AnaptysBio (ANAB) stock dips as rival J&J's (JNJ) trial data for its anti-inflammatory agent similar to ANAB's lead asset disappoints
https://seekingalpha.com/news/4455583-jj-hurts-anaptysbio-anti-inflammatory-data
AnaptysBio (ANAB) stock dips as rival J&J's (JNJ) trial data for its anti-inflammatory agent similar to ANAB's lead asset disappoints
https://seekingalpha.com/news/4455583-jj-hurts-anaptysbio-anti-inflammatory-data
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.